ArticleProceedings of the National Academy of Sciences of the United States of America2017
CD1b-restricted GEM T cell responses are modulated by
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Review
- Th2 bias and T-cell exhaustion characterize the immunopathology of non-tuberculous mycobacterial pulmonary disease.NPJ systems biology and applications · 2026Article
- Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses.Biomolecules · 2025Review
- Establishment of CD1b-restricted immunity to lipid antigens in the pulmonary response toInfection and immunity · 2024Article
- Molecular Modeling and Simulation of the Mycobacterial Cell Envelope: From Individual Components to Cell Envelope Assemblies.The journal of physical chemistry. B · 2023Review
- Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from Mycobacterium tuberculosis challenge.Scientific reports · 2023Article
- Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments.Nanomedicine : nanotechnology, biology, and medicine · 2023Review
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Advanced therapeutics · 2022Article
- CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells.Nature communications · 2022Article
- Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review.Frontiers in immunology · 2022Review
- Immunological hyporesponsiveness in tuberculosis: The role of mycobacterial glycolipids.Frontiers in immunology · 2022Review
- A simple assay to quantify mycobacterial lipid antigen-specific T cell receptors in human tissues and blood.PLoS neglected tropical diseases · 2021Article
- Chemical Synthesis of Cell Wall Constituents ofChemical reviews · 2021Review
- The role of donor-unrestricted T-cells, innate lymphoid cells, and NK cells in anti-mycobacterial immunity.Immunological reviews · 2021Review
- T Cells Specific for a Mycobacterial Glycolipid Expand after Intravenous Bacillus Calmette-Guérin Vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Elevated serum antibody responses to synthetic mycobacterial lipid antigens among UK farmers: an indication of exposure to environmental mycobacteria?RSC medicinal chemistry · 2021Article
- Role of Group 1 CD1-Restricted T Cells in Host Defense and Inflammatory Diseases.Critical reviews in immunology · 2021Article
- Structural Dynamics of the Lipid Antigen-Binding Site of CD1d Protein.Biomolecules · 2020Article
- α-Glucuronosyl and α-glucosyl diacylglycerides, natural killer T cell-activating lipids from bacteria and fungi.Chemical science · 2020Article
- The mycobacterial cell envelope - a moving target.Nature reviews. Microbiology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 6 institutions in 4 countries.
Andrew ChancellorAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Anna S TochevaAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Chris Cave-AylandSchool of Chemistry, University of Southampton, Southampton SO17 1BJ, United Kingdom.
Liku TezeraAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Andrew WhitePublic Health England, National Infections Service, Porton Down, Salisbury SP4 0JQ, United Kingdom.
Juma'a R Al DulayymiSchool of Chemistry, Bangor University, Bangor, Gwynedd LL57 2UW, United Kingdom.
John S BridgemanCellular Therapeutics Ltd, Manchester M13 9XX, United Kingdom.
Ivo TewsSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom.
Susan WilsonAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Nikolai M LissinImmunocore Ltd., Abingdon, Oxon OX14 4RY, United Kingdom.
Marc TebrueggeAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Ben MarshallAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Sally SharpePublic Health England, National Infections Service, Porton Down, Salisbury SP4 0JQ, United Kingdom.
Tim ElliottInstitute for Life Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom.
Chris-Kriton SkylarisSchool of Chemistry, University of Southampton, Southampton SO17 1BJ, United Kingdom.
Jonathan W EssexSchool of Chemistry, University of Southampton, Southampton SO17 1BJ, United Kingdom.
Mark S BairdSchool of Chemistry, Bangor University, Bangor, Gwynedd LL57 2UW, United Kingdom.
Stephan GadolaAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Paul ElkingtonAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
Salah MansourAcademic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom; s.mansour@soton.ac.uk.
University of Southampton · GBPublic Health England · GBBangor University · GBCellular Therapeutics (United Kingdom) · GBImmunocore (United Kingdom) · GBNew York University · US
Funding
Targeting matrix metalloproteinases to limit immunopathology in airborne infectioR33AI102239 · NIAID · UNIVERSITY OF SOUTHAMPTON · PI ELKINGTON, PAUL TIMOTHY · 2014 to 2016
$1.1MCancer Research UK 16997Cancer Research UK 23562Cancer Research UK A23562Medical Research Council MR/N006631/1NIAID NIH HHS R33 AI102239
Abstract
Tuberculosis (TB), caused by
Indexed as
Antigens, BacterialAntigens, CD1Gene ExpressionGranulomaHumansImmunohistochemistryLymphocyte ActivationModels, MolecularMolecular ConformationMycobacterium tuberculosisMycolic AcidsProtein BindingReceptors, Antigen, T-CellT-LymphocytesTuberculosisAntigens, BacterialAntigens, CD1CD1b antigenMycolic AcidsReceptors, Antigen, T-CellCD1bGEM T cellsmolecular dynamicsMycobacterium tuberculosismycolate lipids
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.